<DOC>
	<DOCNO>NCT02970851</DOCNO>
	<brief_summary>The purpose study assess effect bosentan myocardial metabolism dependent endothelial coronary vasomotoricity patient present PAH . Hypothesis : Bosentan may improve right ventricular function decrease myocardial stress glucose metabolism . Patients may benefit image 18F-FDG PET / CT 82Rb PET / CT earlier assessment optimal management PAH .</brief_summary>
	<brief_title>Bosentan Myocardium Metabolism Perfusion Measured 18F-2-fluoro-2-deoxy-D-glucose ( 18F-FDG ) Rubidium-82 ( 82Rb ) Positron Emission Tomography/Computed Tomography ( PET/CTs ) Pulmonary Arterial Hypertension ( PAH ) Chronic Thromboembolic Pulmonary Hypertension ( CTEPH )</brief_title>
	<detailed_description>Patients refer hospital right heart catheterization PAH suspect echocardiography present protocol.If inclusion/exclusion criterion fulfil procedure plan . At screen visit patient right heart catheterization echocardiography . After maximum 4 week patient 18F-FDG 82Rb PET/CTs start treatment Bosentan . These PET/CTs together echocardiography repeat 6 12 week start treatment bosentan . Finally right heart catheterization plan 12 week start treatment bosentan routine procedure .</detailed_description>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Patients chronic PAH ( PH group 1 Dana Point / stag 2 à 4 accord NYHA classification , define mean arterial pulmonary pressure &gt; 25 millimeter mercury ( mmHg ) rest , occlusion arterial pulmonary pressure &lt; 15 millimeter mercury ( mmHg ) vascular pulmonary resistance &gt; 240 dyn.s.cm5 treatment bosentan indicate Or Patients CTEPH candidate pulmonary endarterectomy patient residual CTEPH pulmonary endarterectomy ( PH group 4 Dana Point / stag 2 4 accord NYHA classification ) treatment bosentan indicate Indication perform right heart catheterization context PAH suspect cardiac ultrasound Age 18 80 year old , male female Karnofsky index ≥80 % Informed consent sign Patients PAH stag 2,3 5 Dana Point Patients contraindication adenosine include severe uncontrolled asthma , severe uncontrolled chronic obstructive pulmonary disease , 2nd 3rd degree atrioventricular block without pacemaker , Patients contraindication Bosentan , i.e : hypersensibility product , hepatic failure Child Pugh B C , aminotransferases &gt; 3 time normal value ( N ) , association cyclosporine A glibenclamide Pregnancy , female childbearing potential use acceptable contraceptive method , breastfeed Atrial fibrillation ( Ventricular Ejection Fraction ( VEF ) evaluable echography ) Karnofsky index &lt; 80 % Impossibility obtain informed consent sign Left cardiopathy responsible postcapillar hypertension Involvement another clinical study unregistered drug within 30 day prior specific study entire course study Inability comply study procedure ( linguistic problem , psychiatric problem , dementia , confusional state ) Known suspect non compliance drug alcohol abuse Left heart assessment : diastolic systolic function valvular structure exclude cardiac pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Endothelin receptor antagonist ( ERA )</keyword>
	<keyword>pulmonary artery hypertension ( PAH ) ,</keyword>
	<keyword>18F-2-fluoro-2-deoxy-D-glucose ( 18F-FDG ) Positron Emission Tomography/Computed Tomography ( PET/CT )</keyword>
	<keyword>Rubidium-82 ( 82Rb ) PET/CT</keyword>
</DOC>